Welcome to our dedicated page for I-MAB American Depositary Shares news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-MAB American Depositary Shares stock.
I-Mab American Depositary Shares (Nasdaq: IMAB) represent a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel and highly differentiated biologics to treat diseases with unmet medical needs, focusing on cancers and autoimmune disorders. With operations in Rockville, Maryland, and San Diego, California, I-Mab is actively involved in groundbreaking research and innovative drug development.
The company’s pipeline includes several promising candidates:
- Felzartamab (TJ202): A CD38 antibody in Phase III trials for multiple myeloma and autoimmune diseases.
- Eftansomatropin (TJ101): A long-acting human growth hormone that has completed Phase II trials for pediatric growth hormone deficiency.
- Olamkicept (TJ301): An IL-6 blocker in Phase II trials for ulcerative colitis and autoimmune diseases.
- Enoblituzumab: A humanized B7-H3 antibody that has completed Phase I trials for head and neck cancer and other oncology diseases.
- Efineptakin (TJ107): A long-acting recombinant human IL-7 in Phase II trials for glioblastoma multiforme (GBM).
I-Mab's innovative pipeline is driven by its internal R&D strategies, Fast-to-Proof-of-Concept, and Fast-to-Market development, often in collaboration with global partners. Recently, I-Mab announced the divestiture of its Chinese assets and operations, aiming to focus on the U.S. and other international markets. This strategic move included the transfer of its Greater China rights for various assets, potentially generating up to US$80 million based on future milestone achievements.
Notably, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to evaluate givastomig combined with nivolumab and chemotherapy as a first-line treatment for advanced Claudin 18.2-positive gastric and esophageal cancers. I-Mab’s robust development pipeline and strategic global partnerships exemplify its commitment to advancing novel therapies to address critical medical needs.
For the latest updates and detailed information, visit the official website at I-Mab Biopharma.
I-Mab (Nasdaq: IMAB) announces an investor call on November 13, 2020, at 8:20 a.m. ET, to discuss preliminary results from a Phase 1 clinical trial evaluating lemzoparlimab for relapsed or refractory solid tumors. This call aims to provide detailed analysis of clinical efficacy signals from the trial, recently presented at the 2020 Society for Immunotherapy of Cancer Annual Meeting. The Company is advancing further studies of lemzoparlimab in combination with other treatments like Keytruda and Rituxan.
I-Mab (Nasdaq: IMAB) announced new preclinical data for its C5aR antibody project, TJ210/MOR210, at the SITC Annual Meeting. The data will be presented on November 12, 2020. TJ210/MOR210, developed in collaboration with MorphoSys, is an anti-C5aR monoclonal antibody designed to inhibit tumor-promoting cells. Key findings show high affinity binding to C5aR1, significant tumor growth inhibition in combination with anti-PD-1 therapy, and a favorable safety profile in toxicity studies. The FDA recently approved an IND application to initiate a phase 1 trial for advanced solid tumors.
I-Mab (Nasdaq: IMAB) announced initial results from its Phase 1 clinical trial (NCT03934814) of lemzoparlimab for treating relapsed or refractory solid tumors and lymphoma. Presented at the 2020 SITC Annual Meeting, lemzoparlimab showed strong anti-tumor activity with no dose-limiting toxicity or signs of hemolytic anemia at doses up to 30 mg/kg. Of the 20 patients, one achieved a confirmed Partial Response. Ongoing recruitment for combination therapies with pembrolizumab and rituximab is in progress, reflecting I-Mab's commitment to advancing this innovative treatment.
I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in several upcoming investor conferences in November 2020. Notable events include the 11th Credit Suisse China Investment Conference and the 15th Citi China Investor Conference, where management will engage in one-on-one meetings. The company aims to showcase its innovative pipeline in immuno-oncology and autoimmune diseases, emphasizing its shift towards becoming a fully integrated global biopharmaceutical company. For more details, visit I-Mab's website.
I-Mab (Nasdaq: IMAB) announced its plan to present preclinical data for its anti-C5aR monoclonal antibody, TJ210, at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 9-14, 2020. The data aims to support TJ210's use as a monotherapy or in combination with anti-PD-1 therapies in cancer treatment. TJ210 is designed to inhibit pro-tumor cell recruitment in the tumor microenvironment, potentially enhancing immune response against cancer.
I-Mab (Nasdaq: IMAB) announced it will present findings from its U.S. phase 1 trial of lemzoparlimab (TJC4), a novel anti-CD47 monoclonal antibody, at the SITC 2020 annual meeting from November 9-14. The data will cover safety, pharmacokinetics, pharmacodynamics, receptor occupancy, and preliminary efficacy of the drug in treating relapsed or refractory malignancies. Lemzoparlimab aims to minimize the side effects commonly associated with similar therapies, marking a significant advancement in cancer treatments. The partnership with AbbVie is expected to enhance its development and commercialization efforts.
I-Mab (Nasdaq: IMAB) announced that the China Center for Drug Evaluation has approved the pivotal trial for eftansomatropin (TJ101) as a weekly treatment for pediatric growth hormone deficiency (PGHD). This marks a significant milestone for I-Mab and potential therapies for PGHD patients. Eftansomatropin, utilizing innovative hyFc® technology, aims to provide a safer and more effective alternative to daily injections. The phase 3 trial will compare its efficacy and safety against Norditropin, targeting a market where only 3.7% of 3.4 million pediatric patients currently receive treatment.
I-Mab (Nasdaq: IMAB) has received clearance from China's NMPA for initiating a phase 1 clinical trial of lemzoparlimab, an anti-CD47 monoclonal antibody, in patients with relapsed or refractory advanced lymphoma. The trial follows positive preliminary results from an ongoing phase 1 trial in the U.S., demonstrating safety and favorable pharmacokinetics with no severe hematologic adverse events. Additionally, a phase 1/2a trial in acute myeloid leukemia is underway. I-Mab has established a global partnership with AbbVie for the development and commercialization of lemzoparlimab, retaining rights for mainland China, Macau, and Hong Kong.
MorphoSys and I-Mab announced that the FDA has approved the Investigational New Drug (IND) application for MOR210/TJ210, a monoclonal antibody targeting C5aR1, aimed at treating relapsed or refractory advanced solid tumors. The Phase 1 trial will evaluate the drug's safety and efficacy, following promising preclinical results. This collaboration, initiated in November 2018, allows I-Mab exclusive rights for development in Greater China and South Korea, while MorphoSys retains rights elsewhere. The trial is set to start soon, marking a significant advancement in cancer treatment.
I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in several September conferences. Key events include the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, Jefferies Virtual Asia Forum on September 16, and the ICBCI Virtual ADR New Economy Conference on September 18, among others. Notable presenters include Dr. Jingwu Zang and Dr. Joan Huaqiong Shen, providing insights into the company's innovations in immuno-oncology and autoimmune diseases. I-Mab is focused on transitioning to a fully integrated global biopharmaceutical company.
FAQ
What is the current stock price of I-MAB American Depositary Shares (IMAB)?
What is the market cap of I-MAB American Depositary Shares (IMAB)?
What is I-Mab's core focus?
What are some key products in I-Mab's pipeline?
Where are I-Mab's main operations located?
What recent strategic move has I-Mab made?
What is felzartamab?
Who is I-Mab collaborating with on givastomig?
How does I-Mab fund its operations and research?
What is the significance of the FDA's Breakthrough Therapy designation for felzartamab?
What is I-Mab's approach to drug development?
How can investors stay updated on I-Mab's progress?
